key: cord-0072871-9au65857
authors: Dzik, Sunny; Murphy, Michael
title: Recommended Papers of 2021 From the TMR Editorial Board
date: 2021-12-11
journal: Transfus Med Rev
DOI: 10.1016/j.tmrv.2021.12.001
sha: 412c0d5ffb07c0280afc9e2d37a8d7da57e2a9c1
doc_id: 72871
cord_uid: 9au65857

nan

Transfusion Medicine Reviews xxx (xxxx) xxx

Transfusion Medicine Reviews journal homepage: https://www.journals.elsevier.com/transfusion-medicine-reviews

Recommended Papers of 2021 From the TMR Editorial Board

As we begin 2022, the Editorial Board of Transfusion Medicine Reviews extends to all readers our best wishes for a joyous and healthy year ahead. The Editorial Board selected papers published in 2021 which have special merit, and these are summarized below. We invite readers to become familiar with each of these works which required tremendous dedication by the investigators during the 2021 pandemic year. The dozen papers summarized here cover a range of topics in transfusion medicine. There is something for everyone.

At this juncture last year, high hopes existed for the use of convalescent plasma as a treatment for . Last year, our summary of papers included 1 report on this topic, the RECOV-ERY trial. This year, our summary begins where we left off and summarizes 4 additional key papers on the role of convalescent plasma in Covid-19 infection. The work by Bégin et al includes a meta-analysis of convalescent plasma therapy. Another metaanalysis was recently published by Snow TAC et al (Brit J Anesthesia 2021. https://doi.org/10.1016/j.bja.2021.07.033 ).

One theme that stood out last year was the finding that clinical practices considered to be "standard of care" were found to have little or no value when tested in randomized controlled trials. Remarkably, this year, that same theme is sustained; and readers will see that careful clinical investigation of established transfusion therapy can yield important and surprising results. Trials demonstrating lack of benefit appear this year for transfusions of red blood cells, fresh frozen plasma, albumin, and fibrinogen. REMAP-CAP writing committee. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA 2021; 326:1690 -1702 Topic: Convalescent plasma Design/study group: Multicenter trial based in the UK that enrolled and randomized critically ill adults with COVID-19 between March 2020 and January 2021. The study was conducted in 4 countries. Within the overall study, 2011 patients were randomized to receive convalescent plasma or no plasma.

Intervention: The treatment group ( n = 1084) received 2 units of high-titer ABO compatible convalescent plasma (550 mL ± 150) within 48 hours of randomization. All convalescent plasma used in the trial was tested for SARS-CoV-2 antibodies and met a minimum titer criterion for convalescent plasma in each country participating in the trial. The control group ( n = 916) received the same general care but no plasma.

Findings: The primary outcome was days alive and free of organ support within intensive care during the 21 days following ran-domization. 99% of enrolled subjects completed the trial. The trial was stopped due to prespecified definition of futility of treatment. Futility was defined as an odds ratio following plasma treatment of less than 1.2 for survival or freedom from organ support. Patients who died were assigned a value of -1 for days free of organ support. The median number of days free of organ support was 0 (interquartile -1 to 16) for the plasma group and 3 (interquartile -1 to 16) for the nonplasma group. Hospital mortality was 37.3% in the convalescent plasma group and 38.4% in the no plasma group. The median number of days alive and free of organ support was 14 days in both groups. The likelihood (posterior probability) that convalescent plasma was a futile treatment was 99.4%. Serious adverse events were reported in 3.0% of the convalescent plasma group and 1.3% of the no plasma group.

Conclusion: Among critically ill patients with COVID-19, treatment with 2 units of high-titer convalescent plasma conferred no benefit.

Why is this important? As the global tragedy of COVID-19 unfolded, there was strong enthusiasm for the use of convalescent plasma as a treatment. Some were so convinced by small uncontrolled studies and low-quality historical studies that they did not embark on controlled trials. Not surprisingly, patients who were most critically ill and struggling to survive were the first focus for the use of convalescent plasma. This study, based in the UK, took on the challenge to define the benefit, if any, of convalescent plasma for the critically ill in a large multicenter randomized controlled trial. The study found a very clear absence of benefit and the investigators closed the study when it met predefined evidence for futility. While this expert clinical investigation answered the important question about plasma treatment for the critically ill, plasma was also being applied to other cohorts with COVID-19. Results of studies in those cohorts follow.

Bégin P, Callum J, Jamula E, et al Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Med 2021; 27:2012 -2024 Topic: Convalescent plasma Design/study group: Multicenter randomized trial testing the efficacy of Covid-19 convalescent plasma in adults with Covid-19 infection who were receiving oxygen within 12 days of the onset of respiratory symptoms. 940 patients were randomized and data on 921 were available for analysis (intention to treat). The study was conducted between May 2020 and January 2021 at 72 treatment sites in Canada, the United States, and Brazil.

Intervention: Patients were allocated 2:1 to receive either 500 mL of convalescent plasma or standard care. Findings: The primary outcome was a composite of intubation or death by 30 days after randomization. The study was stopped after 78% of the planned enrollment after meeting pre-established criteria for futility. Intubation or death occurred in 32. 4% (199/614) patients in the convalescent plasma arm and 28.0% (86/307) in the no-plasma arm-a difference in relative risk that was not statistically significant. A subgroup analysis of those treated within 3 days of diagnosis (early treatment) also failed to show benefit from convalescent plasma. Patients assigned to receive convalescent plasma had significantly more serious adverse events: 33.4% in the plasma arm vs 26.4% in the no-plasma arm (relative risk 1.27, 95% CI 1.02-1.57, P = .034). While plasma with higher titers of neutralizing antibody outperformed plasma with lower titers, the opposite was true for IgG against the full transmembrane spike protein. Higher titers of this antibody increased the likelihood of adverse reactions.

Conclusion: Use of convalescent plasma did not reduce the risk of intubation or death at 30 days in hospitalized patients with Covid-19.

Why is this important? This large international trial focused on the role of convalescent plasma in hospitalized patients requiring oxygen at the time of treatment. As a group, the patients were not as advanced in their illness at the time of enrollment as those in the REMAP-CAP study. The very meaningful end point-intubation or death-was not reduced by the use of convalescent plasma; and, like the REMAP trial, CONCOR-1 closed the study when it met prespecified criteria for futility. CONCOR-1 also provides an alternative interpretation to the role of antibody titer and specificity in convalescent plasma. The authors raise the interesting idea that plasma with low neutralizing antibody titers is more harmful than no plasma at all, and that the benefit of high titer plasma in studies with no controls might reflect the difference between no effect (high titer) vs harm (low titer). This hypothesis has yet to be confirmed.

Libster R, Perez Marc G, Wappner D, Coviello S, et al.

Early convalescent plasma for high-risk outpatients with Covid-19. N Eng J Med 2021; 384:610-618. Topic: Convalescent plasma Design/study group: Multicenter randomized placebo-controlled trial testing the use of high titer convalescent plasma for the early treatment of Covid-19 in older adults. The study was conducted in 2020 at trial sites and nursing homes in Argentina. Patients were either 75 years or older regardless of co-morbidities or were 65 to 74 years with 1 or more co-morbidity. 160 patients were randomized. The study was stopped prematurely due to a decrease in Covid-19 infections.

Intervention: Patients were treated within 72 hours of the onset of mild symptoms of Covid-19. Convalescent plasma (250 mL) had an IgG titer of > 1:10 0 0 against the spike protein. The placebo was 250 mL of normal saline. Opaque bags were used for blinding.

Findings: The primary outcome was progression of respiratory disease defined as a respiratory rate of ≥30 breaths per minute, an oxygen saturation of < 93% while breathing room air, or both. In the intention to treat population, respiratory disease developed in 16% (13 of 80) who received convalescent plasma and 31% (25 of 80) who received placebo, P = .04 (chi-square). In an exploratory analysis, plasma with IgG titers > 1:3200 resulted in better outcomes.

Conclusion: High titer convalescent plasma given early to elderly patients with mild symptoms reduced the progression to more severe respiratory disease. The authors concluded that high titer plasma could provide a treatment bridge while waiting for availability of vaccines.

Why is this important? This study is one of the few randomized trials that demonstrated a beneficial effect of convalescent plasma. Because of the smaller sample size, the significance of the differ-ence hinges on 1 patient. Had 1 additional person in the convalescent plasma group been categorized as a respiratory progressor, the outcome would not have been statistically significant. Nevertheless, the study's results sustained interest in the use of convalescent plasma applied early in the course of Covid-19 infection and this was taken up in a larger cohort of patients in the SIREN trial described next.

Korley FK, Durkalski-Mauldin V, Yeatts SD, et al. Early convalescent plasma for high-risk outpatients with Covid-19. N Eng J Med 2021; 385:1951 -1960 Topic: Convalescent plasma Design/study group: Multicenter randomized trial testing convalescent plasma vs placebo for the early treatment of Covid-19. Five hundred and eleven patients were enrolled. 257 received convalescent plasma and 254 received placebo infusions. The median symptom duration at the time of treatment was just 4 days.

Intervention: Convalescent plasma had a documented median SARS-CoV-2 neutralizing antibody titer of 1:641 meeting the definition of "high titer" plasma. The treatment group received 1 unit of ABO compatible convalescent plasma. The placebo group received 250 mL of normal saline colored with vitamin A to resemble plasma. Bags were covered to preserve blinding.

Findings: Disease progression occurred in 77 patients (30%) of those receiving convalescent plasma and 81 patients (32%) of those receiving placebo. The risk difference of 1.9% with a 95% confidence interval of -6% to + 9.8%-a risk that was not statistically different in the 2 groups.

Conclusion: High titer convalescent plasma given to high-risk patient within 1 week of symptom onset demonstrated no benefit and did not prevent disease progression.

Why is this important? As the failure of convalescent plasma emerged in the other international trials referred to above, residual proponents of plasma treatment emphasized 2 factors that they believed represented a possible advantage of convalescent plasma: use of sufficiently high titer plasma and use of plasma early in the course of illness. This study addressed those 2 remaining issues head on and found no advantage to the use of convalescent plasma even if given in high titer early in disease. The repeated failure of convalescent plasma when studied in randomized trials stands in very stark contrast to the claims made prior to the conduct of these trials. The story of convalescent plasma is a sobering one and the evidence thus far has demonstrated that plasma was either a worthless or, in some cases, harmful treatment. It remains to be seen whether an advantage to plasma will be found in specific subsets of patients, or whether hyperimmune globulin or monoclonals will make raw plasma therapy seem rudimentary. Widespread vaccination of the population (including the blood donor population that generates routine plasma) will further complicate future controlled trials. For these and other reasons, the studies cited here remind us of the obligation to conduct well-designed clinical investigation.

Ducrocq G, Gonzalez-Juanatey JR, Puymirat E, et al. Effect of a restrictive vs liberal blood transfusion strategy on major cardiovascular events among patients with acute myocardial infarction and anemia. JAMA 2021; 325:552-560. The REALITY trial Topic: Clinical trigger for Red Blood Cell (RBC) transfusion Design/study group: Multicenter trial of RBC transfusion conducted in 35 hospitals in France and Spain between 2016 and 2019 among 668 patients with myocardial infarction. Patients with acute infarction were randomly assigned to receive RBC transfusion for a hemoglobin concentration (Hb) trigger of 8 g/dL or 10 g/dL.

Intervention: RBC transfusion. Findings: The primary outcome was all-cause death, stroke, recurrent myocardial infarction, or emergency revascularization for JID: YTMRV [mNS; December 30, 2021; 13:44 ] ischemia during the first 30 days after randomization. In the restrictive group ( n = 342), 122 patients received transfusion utilizing 342 units of RBCs. In the liberal group ( n = 324), 323 patients received transfusion utilizing 758 units of RBCs. A major adverse outcome occurred in 36 (11%) of those in the restrictive arm and 45 (14%) of those in the liberal arm, a difference which was not statistically significant.

Conclusion: There was no benefit to a liberal transfusion trigger as measured by the frequency of major adverse cardiovascular events.

Why is this important? In 1961 an influential textbook of anesthesia authored by Dr Robert Dripps offered an unreferenced recommendation that patients should be maintained at a hemoglobin > 10 g/dL for major surgery. This trigger became an unchallenged standard for decades. Since 1990 there have been many high quality 'trigger trials' that have randomized patients to a higher or lower Hb threshold for the transfusion of RBCs. None of these trials, collectively enrolling tens of thousands of patients, has shown any benefit for those randomized to receive RBCs at a higher Hb trigger. This includes a recent Canadian trial, published last year, demonstrating equivalent outcomes among 300 patients undergoing hematopoietic stem cell transplantation who were randomly assigned to receive RBC transfusion triggered by a Hb of 7 g/dL vs 9 g/dL (Tay J, et al. J Clin Oncol 2020. doi: 10.1200/JCO.19.01836). However, all the major 'Hb trigger trials' avoided enrollment of patients with acute myocardial ischemia according to the wellentrenched notion that a lower trigger might result in insufficient oxygen delivery to the myocardium. This study will be remembered as a landmark effort to address the Hb trigger in the unique cohort of patients with acute myocardial ischemia. As was true for all previous randomized trigger trials, Decrocq et al found that there was no advantage to a liberal Hb threshold of 10 g/dL. Of particular note, 1 in 10 patients in either arm experienced complications potentially attributed to insufficient oxygen delivery. The deeper lesson in this trial, and in all trigger trials, is that Hb concentration is not a good indicator of tissue oxygenation. With the question of Hb trigger now addressed in this final patient cohort, it is hoped that clinical investigators will focus on new methods to assess tissue oxygenation by transfusion. Multicenter trial of RBC transfusion conducted between December 2012 and April 2017among 1824 low birth weight infants ( < 10 0 0 g) and a gestational age between 22 weeks and 28 weeks 6 days.

Intervention: Patients were randomly assigned to receive RBC transfusion to maintain a higher hemoglobin concentration (Hb) (average 12 g/dL) vs a lower Hb (10 g/dL).

Findings: The primary outcome was a composite of death or impaired neurodevelopment (as measured by cognitive delay, cerebral palsy, or loss of hearing or vision) measured at 22-26 months. Among 845 infants randomized to the higher Hb, 423 (50.1%) died or survived with neurologic impairment. Among 847 infants assigned to the lower Hb, 422 (49.8%) died or survived with neurological impairment. The 2 groups were not different for the primary outcome. The 2 groups were also not different for the incidence of complications at discharge from hospital, for serious adverse events, or at follow up at 2 years.

Conclusion: Among premature low birth weight infants, there was no benefit to a liberal RBC transfusion trigger as measured by the frequency of death or neurological impairment.

Why is this important? Randomized trials in critically ill newborns are difficult and require enormous dedication from all partic-ipants. This study validates and confirms previous work to indicate that maintaining Hb concentrations at high levels by transfusion does not improve clinical outcomes. For some readers, the study's primary finding will not be a surprise given that the study compared maintaining a Hb > 12 g/dL vs > 10 g/dL. Healthy newborns have a high Hb, and it is understandable that the investigators would design the study to maintain higher levels than found in other clinical circumstances. However, the higher Hb found in newborns does not actually mean that a higher Hb is required by the newborn. In fact, we do not know if the higher Hb values of newborns are a necessary requirement for survival and normal brain development or are simply a compensation for the lower tissue oxygen delivery that routinely occurs in utero. The TOP trial documents that a concentration of 12 g/dL is no better than 10 g/dL for premature infants. The trial also serves as a startling reminder of the severity of illness that accompany transfusion studies. Half of the children in this studied died or survived with serious neurological impairment. Topic: Plasma transfusion prior to invasive procedure Design/study group: Pilot study in hospitalized patients with an INR between 1.5 and 2.5 who were undergoing an invasive bedside procedure. Procedures related to the central nervous system including the spinal cord were excluded from study. Patients with thrombocytopenia ( < 40,0 0 0/μL) or coagulation disorders known to be unresponsive to plasma were also excluded. The pilot study was not powered to provide a conclusive outcome.

Intervention: Those randomized to preprocedure plasma received 10-15 mL/kg. The control arm received no infusion.

Findings: The primary outcome was a change in hemoglobin concentration (Hb) measured within 2 days of the procedure. The study enrolled 57 patients. The mean (standard deviation) change in Hb within 2 days among 27 patients randomized to receive plasma was -0.6 (1.0); whereas the mean change in the 30 controls was -0.4 (0.6). The change in the 2 groups was not significantly different. Postprocedure INR results were improved by plasma: a higher percentage of patients in the plasma arm (38.5%) had a postprocedure INR < 1.5 compared with only 3.6% of those not transfused, P < .01. Among 22 patients receiving at least 10 mL/kg of plasma, 45% had a postprocedure INR < 1.5.

Conclusion: In a small pilot study, there was no effect of preprocedure plasma on bleeding as measured by drop in Hb within 2 days.

Why is this important? The results of this pilot study likely come as no surprise to transfusion medicine professionals who have followed the story of preprocedure plasma transfusion. Carson et al used decline-in-hemoglobin during the 48 hours after a procedure as an objective surrogate for significant bleeding and were unable to demonstrate that preprocedure plasma influenced that measure. Plasma did lower the INR below 1.5 in one-third of patients transfused. Rather than the outcome, the study may be of particular significance to indicate the difficulty of resolving whether preprocedure plasma has any value. The investigators screened 534 patients in order to report results on 57 individuals. The patients ultimately included were mostly those with cirrhosis-a condition where the INR assay, which was used as an entry criterion, may reflect a coagulation disorder that is quite different from that found in patients with other causes of INR elevation. Cirrhotic patients frequently have intravascular volume expansion and the understandable concern regarding additional volume infusion by plasma was one of several reasons why clinicians did not wish to enroll patients in the trial. In what may seem like the Transfusion Medicine equivalent of "whack-a-mole," plasma use is generally on the de- JID: YTMRV [mNS; December 30, 2021; 13:44 ] cline, but fibrinogen use is on the rise. Our next selection focuses on fibrinogen. Obstetrics and Gynaecology 2021; 128:1814 -1823 Topic: Fibrinogen concentrate transfusion for postpartum hemorrhage Design/study group: Multicenter blinded randomized trial conducted in France testing whether infusions of fibrinogen concentrate would improve outcomes in women with postpartum bleeding following vaginal delivery. 437 patients were randomized. Treatment began within 30 minutes of use of prostaglandins. Women were > 18 years of age, had vaginal bleeding > 500 mL following delivery, and were receiving treatment with intravenous prostaglandin (sulprostone).

Intervention: Those randomized to fibrinogen received 3 grams of concentrate whereas the control group received an otherwise identical placebo. The primary outcome was treatment failure assessed at 48 hours after delivery and defined as either a > 4 g/dL drop in hemoglobin or the transfusion of 2 or more units of red blood cells.

Findings: Of the 437 patients, 224 received fibrinogen concentrate and 213 received placebo. At the time of infusion, the 2 groups were similar (by randomization) for blood loss (877 ± 346 mL) and for fibrinogen concentration (4.1 ± 0.9 g/L). Treatment failure occurred in 40% of the fibrinogen group and 42.4% of the placebo group-a difference that was not statistically significant.

The group randomized to placebo demonstrated a drop in plasma fibrinogen by 0.56 g/L which was of no discernable clinical consequence.

Conclusion: Routine transfusion of fibrinogen concentrate for women with postpartum bleeding is of no demonstrable value.

Why is this important? Following a few retrospective studies that demonstrated an association between lower range fibrinogen concentrations and the volume of postpartum hemorrhage, clinician investigators were quick to make recommendations for use of fibrinogen to achieve levels that are commonly observed in term pregnancy, but that are higher than average for nonpregnant patients. Subsequent randomized trials of smaller sample size failed to demonstrate value from routine fibrinogen supplementation in postpartum hemorrhage. This multicenter trial from France studied over 400 patients with postpartum bleeding after vaginal delivery and documents no value obtained from the routine administration of fibrinogen concentrate. The recommendations for high fibrinogen levels that began in pregnant patients have spilled over to other clinical arenas without controlled trial proof of reduction in bleeding. We hope that those promoting routine supplementation to achieve high fibrinogen levels in trauma, cardiac surgery, general surgery, and transplantation will offer conservative opinions until data demonstrating clinical efficacy is presented. J Med 2021; 384:808-817. ATTIRE Topic: Albumin infusions in liver disease Design/study group: Multicenter randomized trial testing whether infusions of albumin improved outcomes in hospitalized patients with decompensated cirrhosis and an albumin level < 30 g/L. 777 patients were randomized. Treatment began within 3 days of admission.

Intervention: Those randomized to albumin infusions received 20% albumin intravenously to maintain an albumin level > 30 g/L for up to 14 days or discharge. The primary outcome was a com-posite of new infection, kidney dysfunction, or death between 3 and 15 days after beginning albumin treatment.

Findings: Among 397 patients randomized to receive albumin, a median total of 200 g (interquartile 140-280) of albumin was administered. This represents 16 bottles/bags per patient as formulated in the USA. A median of 20 g (interquartile 0-120) of albumin per patient was given to those who were assigned to the standard care group ( n = 380). The percentage of patients with any of the composite primary adverse outcomes was 29.7% (120 of 397) in the albumin group and was 30.2% (113 of 380) in the standard care group, a difference that was not statistically significant. A time to event analysis also showed no difference between the 2 groups.

Conclusion: Among hospitalized patients with advanced cirrhosis, albumin infusions given to maintain a target goal of 30 g/L provided no benefit over standard care for serious outcomes.

Why is this important? As a supplier of albumin to hospitalized patients, I heard for decades the argument that hypoalbuminemia contributes to adverse outcomes in cirrhosis. Embedded in the argument are some classic pitfalls: advanced cirrhosis is indeed associated with low albumin and advanced cirrhosis is associated with adverse outcomes, but the mutual association does not indicate causality. More to the point, changing the laboratory value (albumin level) by infusing albumin does not necessarily change the course of liver disease any more than artificially lowering the bilirubin level would correct cirrhosis. And yet, enormous quantities of albumin have been given to patients with advanced liver disease under the assumption of value. This well-designed randomized trial from the UK demonstrates no added value to routine albumin infusions given to achieve some target level. The study falls into the lamentable tradition of transfusion given to correct a laboratory value and can be aligned with others presented here on red cells, plasma, and fibrinogen. Topic: Viscoelastic testing vs conventional coagulation testing in trauma Design/study group: Multicenter randomized trial that compared massive hemorrhage protocols incorporating viscoelastic testing vs conventional coagulation testing. The study was conducted at 7 major trauma centers in Europe. Two-thirds of the patients were victims of blunt trauma. The overall median injury severity score was 26 (interquartile 17-36) where a score > 15 indicates severe trauma. Tranexamic acid was used in 95% (377/396) of cases.

Intervention: Use of thromboelastography (TEG) or thromboelastrometry (ROTEM) vs conventional testing as part of the resuscitation algorithm. Participants were randomized within 3 hours of injury and within 1 hour of arrival to the emergency department.

Findings: The primary outcome was the proportion of patients who at 24 hours after injury were alive and free of massive transfusion. A secondary outcome was 28-day mortality. Among 396 patients randomized, 201 were assigned to viscoelastic testing and 195 to conventional testing. There was no difference in the proportion of patients alive and free of massive transfusion at 24 hours: 67% (135/201) in the viscoelastic arm vs 64% (125/195) in the conventional testing arm, P = .52 (chi-square). Survival at 28 days was not different in the 2 groups. There were no differences in other secondary outcomes nor in comparisons among prespecified subgroups (eg, traumatic brain injury). An important secondary finding was that patients assigned to the viscoelastic testing group received interventions (such as transfusion) 1.8 times more than the conventional group. JID: YTMRV [mNS; December 30, 2021; 13:44 ] Conclusion: Massive hemorrhage protocols supplemented by viscoelastic testing do not improve outcomes compared with protocols guided by conventional coagulation testing.

Why is this important? Although viscoelastic testing was developed in the 1940s, there has been substantial renewed interest in the use of TEG and ROTEM both as diagnostics and as a guide to transfusion resuscitation. Interest has been especially strong among those in the field of trauma. Many uncontrolled reports have been published and the topic appears to elicit strong opinions on all sides. This study is important because it represents a substantial effort to identify whether viscoelastic testing adds value over conventional testing in the resuscitation of trauma patients. The study was randomized, multicenter, and conducted by expert trauma centers familiar with resuscitation protocols of the International Trauma Research Network. The sample size of nearly 400 patients was more than adequate to observe an important treatment effect. The primary outcome was relevant and objective. The results show that, in the setting studied, viscoelastic testing did not demonstrate any clinical advantage over conventional coagulation testing. The more liberal use of transfusion in the viscoelastic testing arm with no discernable improvement in outcome might suggest that current transfusion algorithms based on TEG and ROTEM testing are overly liberal and use more blood products to no final advantage. The study deserves a very careful reading by all who might consider that they should 'convert' from whatever testing they are currently doing to viscoelastic testing. It also suggests that what dominates survival and freedom from on-going massive hemorrhage may have more to do with surgical and anesthesia skill than with laboratory testing.

Taeuber I, Weibel S, Herrmann E, et al. Association of intravenous tranexamic acid with thromboembolic events and mortality: a systematic review, meta-analysis, and meta-regression. JAMA Surgery 2021 . doi:10.1001 /jamasurg.2021 Topic: Anti-fibrinolytic therapy Design/study group: Review of the Cochrane Register of Controlled Trials and MEDLINE for studies published between 1976 and 2020 that investigated the use of intravenous tranexamic acid vs placebo or tranexamic acid vs no-treatment. The primary focus of the review was the frequency of thromboembolic events. The authors analyzed studies published in English, German, French, and Spanish. Studies using topical or oral tranexamic acid were excluded.

Findings: 216 trials involving 125,550 patients were analyzed. The overall rate of thromboembolic events was 2.1% in the tranexamic acid group vs 2.0% in the control group-a risk difference that was not statistically significant. There was no association between use of tranexamic acid and risk of specific thromboembolic events including venous thrombosis, pulmonary embolism, venous thromboembolism, myocardial infarction or ischemia, and cerebral infarction or ischemia. A regression analysis across 143 intervention groups found no association between the dose of tranexamic acid and risk of thromboembolism.

Conclusion: The results suggest that intravenous tranexamic acid, regardless of dose, is not associated with an increased risk for any form thromboembolic complication.

Why is this important? By interfering with the localization of plasminogen and plasmin on to lysine residues of fibrinogen and fibrin, tranexamic acid reduces clot lysis. Despite widespread use, some clinicians harbor concerns that tranexamic acid will increase the risk of thromboembolic complications. A weak signal for such complications was reported in some studies, such as the HALT-IT trial in gastrointestinal bleeding which observed a 0.4% increased risk of thromboembolic events in those randomized to tranexamic acid. Other major trials which have shown improvement in clinical outcomes using tranexamic acid, such as the CRASH-2, observed no increased risk. This paper used meta-analysis to combine outcomes from over 10 0,0 0 0 patients and failed to identify an increased risk of thromboembolic events in patients treated with tranexamic acid.

Wu SC, Arthur CM, Wang J, et al. The SARS-CoV-2 receptor binding domain preferentially recognizes blood group A. Blood Advances 2021; 5:1305 -1309 Topic: ABO blood groups and SARS-CoV-2 Design/study group: The investigators cloned the virus receptor binding domain (RBD). The RBD was incubated with either a Tcell line which expresses angiotensin-converting enzyme (ACE2), the natural ligand for the RBD or with Red Blood Cells. Binding of the cloned RBD to either the T cells or the Red Cells was assessed by flow cytometry. In part 2 of the study, RBD was incubated with synthetic glycan arrays that included glycans found in Type 1 ABO structures.

Findings: The synthetic RBD structure showed no preference for group A red blood cells as measured by flow cytometry. However, in the microarray glycan assay, the RBD structure showed clear preference for Type 1 A glycan.

Conclusion: There was no evidence that the RBD domain of SARS-CoV-2 preferentially binds to group A red cells. The domain showed binding preference for Type 1 A-structures that may be found in the respiratory epithelium.

Why is this important? The association of ABO blood groups with the SARS-CoV-2 virus continues to fascinate and perplex. The popular press has, not surprising, misrepresented the issue which can produce confusing and misleading information about the risk of infection and the need for vaccination among individuals of different ABO groups. There are 3 key issues to independently sort out in this fascinating story: one is whether or not there is a biological connection between the virus and ABO glycans; a second issue is whether or not an association exists between ABO group and actual disease transmission (disease acquisition); and a third key issue is whether or not there is an association between ABO group and disease severity/outcome. The 3 issues are not necessarily tightly linked. This paper addresses the first of these considerations using clearly described laboratory assays. The authors found that a cloned construct of the virus receptor binding domain preferentially bound to the Type 1 A-structure expressed on a synthetic glycan array and did not bind strongly to group A red cells. The study provides insight into the possibility that in group A individuals, type 1 A-structures in the respiratory epithelium may compete with or may supplement ACE-2 receptors for RBD binding. Because this was a laboratory investigation and used artificial constructs, no specific conclusion can yet be made about the in vivo relevance of the finding or whether other modifiers such as the Se gene or the presence of ABO antibodies might influence the findings. Despite these natural limitations of in vitro investigation, the study provides refreshingly clear information related to the RBD domain and ABO glycobiology. In contrast, clinical studies in this area remain very muddled. Studies comparing either transmission or outcomes among Covid-19 patients with healthy control populations-especially blood donors-are very flawed because the ethnicity of patients and donors are not matched and because of the obvious fact that blood donor rolls are always enriched for group O individuals. Studies examining outcomes and ABO distribution within a cohort of infected individuals do not introduce the blood donor bias but still do not account for ethnic mix. Because comorbidities influence outcome and because comorbidities can track with socioeconomic status and ethnicity, mere tabulation of ABO distributions can easily lead to false conclusions. For those in transfusion medicine, the study by Wu et al reminds us that the biology could have been otherwise. SARS-CoV-2 could have been a virus highly adherent to human red cells. Imagine the effect that would have had on transfusion practice worldwide.

YTMRV [mNS

The authors have no conflict of interest to disclose in relation to the submitted review.

This research/work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.